Back stories here.
“To thrive in the long run, {Big Pharma} companies cannot simply depend on future returns from new products in their pipelines. As they wake up to new market realities, they must tackle their challenges and address risk in a fundamentally different way, frequently requiring significant transformation”.
Robert Go, Deloitte Touche Tohmatsu Link
No comments:
Post a Comment